- Home
- GHC vs AXSM Comparison
GHC vs AXSM Comparison
Compare GHC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHC
- AXSM
- Stock Information
- Founded
- GHC 1877
- AXSM 2012
- Country
- GHC United States
- AXSM United States
- Employees
- GHC N/A
- AXSM N/A
- Industry
- GHC Other Consumer Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- GHC Real Estate
- AXSM Health Care
- Exchange
- GHC Nasdaq
- AXSM Nasdaq
- Market Cap
- GHC 5.1B
- AXSM 5.9B
- IPO Year
- GHC N/A
- AXSM 2015
- Fundamental
- Price
- GHC $1,024.66
- AXSM $129.09
- Analyst Decision
- GHC
- AXSM Strong Buy
- Analyst Count
- GHC 0
- AXSM 19
- Target Price
- GHC N/A
- AXSM $174.47
- AVG Volume (30 Days)
- GHC 47.3K
- AXSM 455.6K
- Earning Date
- GHC 10-29-2025
- AXSM 11-03-2025
- Dividend Yield
- GHC 0.70%
- AXSM N/A
- EPS Growth
- GHC 426.70
- AXSM N/A
- EPS
- GHC 155.13
- AXSM N/A
- Revenue
- GHC $4,834,649,000.00
- AXSM $495,033,000.00
- Revenue This Year
- GHC $2.76
- AXSM $63.76
- Revenue Next Year
- GHC $7.56
- AXSM $54.57
- P/E Ratio
- GHC $6.59
- AXSM N/A
- Revenue Growth
- GHC 4.73
- AXSM 69.83
- 52 Week Low
- GHC $770.06
- AXSM $75.56
- 52 Week High
- GHC $1,200.00
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- GHC 44.33
- AXSM 60.59
- Support Level
- GHC $933.88
- AXSM $127.49
- Resistance Level
- GHC $1,057.17
- AXSM $134.25
- Average True Range (ATR)
- GHC 42.11
- AXSM 4.31
- MACD
- GHC 1.01
- AXSM 0.44
- Stochastic Oscillator
- GHC 40.50
- AXSM 69.52
About GHC Graham Holdings Company
Graham Holdings Co. is a diversified education and media company made up of subsidiaries. Firm operations include educational services; television broadcasting; online, print, and local news; home health and hospice care; and manufacturing. The Company segments into the following seven reportable segments: Kaplan International, Higher Education, Supplemental Education, Television Broadcasting, Manufacturing, Healthcare, and Automotive. The majority of revenue comes from the Kaplan International segment, which includes higher education, test preparation, language instruction, and professional training. A large portion of company revenue also comes from the television broadcasting segment through advertising.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.